Roy A Jensen

List of Publications by Year
in descending order

101 papers	7,248 citations	76196 40 h-index	60497 81 g-index
103 all docs	103 docs citations	103 times ranked	7841 citing authors

#	Article	IF	Citations
1	Functional characterization of NPM1â€“TYK2 fusion oncogene. Npj Precision Oncology, 2022, 6, 3.	2.3	2
2	Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage Iâ€“III Triple-negative Breast Cancer (NeoSTOP). Clinical Cancer Research, 2021, 27, 975-982.	3.2	51
3	Preclinical Evaluation of Gilteritinib on NPM1-ALKâ€“Driven Anaplastic Large Cell Lymphoma Cells. Molecular Cancer Research, 2021, 19, 913-920.	1.5	5
4	Celastrol and Triptolide Suppress Stemness in Triple Negative Breast Cancer: Notch as a Therapeutic Target for Stem Cells. Biomedicines, 2021, 9, 482.	1.4	19
5	Role of Bitter Taste Receptor TAS2R38 In Colorectal Cancer. FASEB Journal, 2021, 35, .	0.2	0
6	Evaluating the role of RNA binding protein CELF2 in modulating immune cells in colitis. FASEB Journal, 2021, 35, .	0.2	0
7	Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the Î³-secretase complex. Cell Death and Disease, 2021, 12, 562.	2.7	6
8	Honokiol Affects Stem Cell Viability by Suppressing Oncogenic YAP1 Function to Inhibit Colon Tumorigenesis. Cells, 2021, 10, 1607.	1.8	8
9	Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice. Gastroenterology, 2020, 158, 1433-1449.e27.	0.6	23
10	OPTIK: a database for understanding catchment areas to guide mobilization of cancer center assets. Database: the Journal of Biological Databases and Curation, 2020, 2020, .	1.4	3
11	Cucurbitacin B and I inhibits colon cancer growth by targeting the Notch signaling pathway. Scientific Reports, 2020, 10, 1290.	1.6	44
12	Utilization of Technology to Improve Efficiency in Investigational Drug Management Processes. Journal of Pharmacy Technology, 2020, 36, 84-90.	0.5	0
13	Safety, dose tolerance, pharmacokinetics, and pharmacodynamics of fosciclopirox (CPX-POM) in patients with advanced solid tumors.. Journal of Clinical Oncology, 2020, 38, 518-518.	0.8	1
14	RNA Binding Protein RBM3 Modulates Novel LncRNAs to Increase Tumor Progression in Colon Cancer Cells. FASEB Journal, 2020, 34, 1-1.	0.2	0
15	Relevant Word Order Vectorization for Improved Natural Language Processing in Electronic Health Records. Scientific Reports, 2019, 9, 9253.	1.6	9
16	The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice. Gastroenterology, 2019, 157, 1646-1659.e11.	0.6	50
17	Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells. Leukemia, 2019, 33, 1675-1686.	3.3	12
18	Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response. Cancer Research, 2019, 79, 1681-1695.	0.4	40

#	Article	IF	Citations
19	Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 148-159.	1.3	17
20	BRCA1â€"No Matter How You Splice It. Cancer Research, 2019, 79, 2091-2098.	0.4	16
21	Pleotropic role of RNA binding protein CELF2 in autophagy induction. Molecular Carcinogenesis, 2019, 58, 1400-1409.	1.3	26
22	CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas. Blood Cancer Journal, 2019, 9, 14.	2.8	3
23	Targeted Therapy for EBV-Associated B-cell Neoplasms. Molecular Cancer Research, 2019, 17, 839-844.	1.5	7
24	Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells. Blood, 2019, 134, 2865-2865.	0.6	0
25	Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression. Cell Death and Disease, 2018, 9, 326.	2.7	78
26	When the good go bad: Mutant NPM1 in acute myeloid leukemia. Blood Reviews, 2018, 32, 167-183.	2.8	73
27	Mitochondrial polymorphisms contribute to aging phenotypes in MNX mouse models. Cancer and Metastasis Reviews, 2018, 37, 633-642.	2.7	6
28	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clinical Cancer Research, 2018, 24, 5820-5829.	3.2	82
29	Targeting the Prolactin Receptor Signaling Using an Antipsychotic Drug to Suppress Pancreatic Cancer. FASEB Journal, 2018, 32, 610.3.	0.2	0
30	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. Clinical Cancer Research, 2017, 23, 649-657.	3.2	108
31	Mitochondrial Haplotype Alters Mammary Cancer Tumorigenicity and Metastasis in an Oncogenic Driverâ€"Dependent Manner. Cancer Research, 2017, 77, 6941-6949.	0.4	28
32	Clinical Activity of Pembrolizumab in a Patient With Metastatic Triple-Negative Breast Cancer Without Tumor Programmed Death-Ligand 1 Expression: A Case Report and Correlative Biomarker Analysis. JCO Precision Oncology, 2017, 1, 1-6.	1.5	2
33	Current Approaches to Diagnosis and Treatment of Ductal Carcinoma In Situ and Future Directions. Progress in Molecular Biology and Translational Science, 2017, 151, 33-80.	0.9	6
34	Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy. Seminars in Cancer Biology, 2016, 40-41, 192-208.	4.3	217
35	Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells. Oncotarget, 2016, 7, 3217-3232.	0.8	59
36	Essential Components of Cancer Education. Cancer Research, 2015, 75, 5202-5205.	0.4	10

#	Article	IF	Citations
37	Honokiol inhibits melanoma stem cells by targeting notch signaling. Molecular Carcinogenesis, 2015, 54, 1710-1721.	1.3	62
38	Honokiol affects melanoma cell growth by targeting the AMP-activated protein kinase signaling pathway. American Journal of Surgery, 2014, 208, 995-1002.	0.9	23
39	Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Research and Treatment, 2014, 145, 707-714.	1.1	144
40	Prolactin signaling enhances colon cancer stemness by modulating Notch signaling in a Jak2-STAT3/ERK manner. Carcinogenesis, 2014, 35, 795-806.	1.3	61
41	The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer. Journal of Cancer Therapeutics & Research, 2014, 3, 2.	1.2	48
42	BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13650-13655.	3.3	121
43	Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology. Translational Research, 2012, 160, 178-197.	2.2	32
44	RNA Binding Protein CUGBP2/CELF2 Mediates Curcumin-Induced Mitotic Catastrophe of Pancreatic Cancer Cells. PLoS ONE, 2011, 6, e16958.	1.1	65
45	3,5-Bis(2,4-Difluorobenzylidene)-4-piperidone, a Novel Compound That Affects Pancreatic Cancer Growth and Angiogenesis. Molecular Cancer Therapeutics, 2011, 10, 2146-2156.	1.9	19
46	A Human Breast Cell Model of Preinvasive to Invasive Transition. Cancer Research, 2008, 68, 1378-1387.	0.4	145
47	Effects of BRCA1 Transgene Expression on Murine Mammary Gland Development and Mutagen-Induced Mammary Neoplasia. International Journal of Biological Sciences, 2007, 3, 281-291.	2.6	13
48	Excellent survival, cancer type, and Nottingham grade after atypical lobular hyperplasia on initial breast biopsy. Cancer, 2006, 107, 1227-1233.	2.0	36
49	Lobulocentricity of Breast Hypersecretory Hyperplasia With Cytologic Atypia. American Journal of Clinical Pathology, 2004, 122, 714-720.	0.4	14
50	Proteomics in Diagnostic Pathology. American Journal of Pathology, 2004, 165, 1057-1068.	1.9	257
51	An adenoviral vector containing an argâ€“glyâ€“asp (RGD) motif in the fiber knob enhances protein product levels from transgenes refractory to expression. Cancer Gene Therapy, 2003, 10, 559-570.	2.2	13
52	Metaplastic Spindle Cell Breast Tumors Arising within Papillomas, Complex Sclerosing Lesions, and Nipple Adenomas. Modern Pathology, 2003, 16, 893-901.	2.9	129
53	Transgenic Mice Expressing a Dominant-Negative Mutant Type II Transforming Growth Factor-Î² Receptor Exhibit Impaired Mammary Development and Enhanced Mammary Tumor Formation. American Journal of Pathology, 2003, 163, 1539-1549.	1.9	120
54	Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet, The, 2003, 361, 125-129.	6.3	321

#	Article	IF	Citations
55	Atypical Ductal Hyperplasia on Core Biopsy. , 2003, 8, 245-248.		1
56	Atypical Ductal Hyperplasia on Core Biopsy. , 2003, 8, 245-248.		0
57	Ductal Carcinoma In Situ of the Breast. American Journal of Surgical Pathology, 2003, 27, 828-831.	2.1	33
58	A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clinical Cancer Research, 2003, 9, 4695-704.	3.2	102
59	Direct analysis of laser capture microdissected cells by MALDI mass spectrometry. Journal of the American Society for Mass Spectrometry, 2002, 13, 1292-1297.	1.2	153
60	Atypical ductal hyperplasia and ductal carcinoma in situ of the breast associated with perineural invasion. Human Pathology, 2001, 32, 785-790.	1.1	26
61	Core Biopsy of the Breast With Atypical Ductal Hyperplasia. American Journal of Surgical Pathology, 2001, 25, 1017-1021.	2.1	153
62	No elevation in long-term breast carcinoma risk for women with fibroadenomas that contain atypical hyperplasia. Cancer, 2001, 92, 30-36.	2.0	76
63	Construction and characterization of recombinant adenoviruses expressing human BRCA1 or murine Brca1 genes. Cancer Gene Therapy, 2001, 8, 231-239.	2.2	5
64	[35] Analysis of cancer gene functions through gene inhibition with antisense oligonucleotides. Methods in Enzymology, 2000, 314, 499-506.	0.4	2
65	The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene, 2000, 19, 968-988.	2.6	455
66	Historical and epidemiologic background of human premalignant breast disease. Journal of Mammary Gland Biology and Neoplasia, 2000, 5, 341-349.	1.0	18
67	Genetically engineered mouse models of mammary intraepithelial neoplasia. Journal of Mammary Gland Biology and Neoplasia, 2000, 5, 421-437.	1.0	59
68	Benign Transport of Breast Epithelium Into Axillary Lymph Nodes After Biopsy. American Journal of Clinical Pathology, 2000, 113, 259-265.	0.4	204
69	Reactive Spindle Cell Nodules of the Breast After Core Biopsy or Fine-Needle Aspiration. American Journal of Clinical Pathology, 2000, 113, 288-294.	0.4	59
70	BRCA1 Expression Restores Radiation Resistance in BRCA1-defective Cancer Cells through Enhancement of Transcription-coupled DNA Repair. Journal of Biological Chemistry, 1999, 274, 18808-18812.	1.6	203
71	Estrogen replacement therapy in women with a history of proliferative breast disease. , 1999, 85, 1277-1283.		69
72	Metaplastic breast tumors with a dominant fibromatosis-like phenotype have a high risk of local recurrence. , 1999, 85, 2170-2182.		170

#	Article	IF	Citations
73	Immunocytochemical analysis of MNDA in tissue sections and sorted normal bone marrow cells documents expression only in maturing normal and neoplastic myelomonocytic cells and a subset of normal and neoplastic B lymphocytes. Human Pathology, 1999, 30, 1040-1049.	1.1	45
74	Prostatic adenocarcinoma with glomeruloid features. Human Pathology, 1999, 30, 111-112.	1.1	3
75	Caveolin Is an Inhibitor of Platelet-Derived Growth Factor Receptor Signaling. Experimental Cell Research, 1999, 247, 380-388.	1.2	101
76	Benign Breast Lesions. , 1999, , 331-346.		0
77	Monoclonality in fibroadenomas with complex histology and phyllodal features. Breast Cancer Research and Treatment, 1998, 50, 185-191.	1.1	20
78	Routinely available indicators of prognosis in breast cancer. Breast Cancer Research and Treatment, 1998, 51, 195-208.	1.1	62
79	OVARIAN CANCER GENE THERAPY. Hematology/Oncology Clinics of North America, 1998, 12, 539-552.	0.9	14
80	When and to What End Do Pathologists Agree?. Journal of the National Cancer Institute, 1998, 90, 88-89.	3.0	30
81	Gene Therapy for Breast and Ovarian Cancer with BRCA1. Breast Disease, 1998, 10, 89-98.	0.4	7
82	Routinely available indicators of prognosis in breast cancer. , 1998, , 3-16.		0
83	RAP-PCR Using RNA from Tissue Microdissection. , 1997, 85, 277-284.		1
84	High-Mobility Group (HMG) Protein HMG-1 and TATA-Binding Protein-Associated Factor TAF‹sub›II‹/sub›30 Affect Estrogen Receptor-Mediated Transcriptional Activation. Molecular Endocrinology, 1997, 11, 1009-1019.	3.7	66
85	Structure and function analysis of the human myeloid cell nuclear differentiation antigen promoter: Evidence for the role of Sp1 and not of c-Myb or PU.1 in myelomonocytic lineage-specific expression. Journal of Cellular Biochemistry, 1997, 65, 231-244.	1.2	20
86	Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma. , 1996, 78, 258-266.		233
87	Growth retardation and tumour inhibition by BRCA1. Nature Genetics, 1996, 12, 298-302.	9.4	359
88	BRCA1 is secreted and exhibits properties of a granin. Nature Genetics, 1996, 12, 303-308.	9.4	198
89	Reply to â€œâ€¦and secreted tumour suppressorsâ€• Nature Genetics, 1996, 13, 269-272.	9.4	20
90	Continued local recurrence of carcinoma 15â€“25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer, 1995, 76, 1197-1200.	2.0	409

#	Article	IF	Citations
91	Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nature Genetics, 1995, 9, 444-450.	9.4	552
92	Evaluation and management of high risk and premalignant lesions of the breast. World Journal of Surgery, 1994, 18, 32-38.	0.8	36
93	Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions. Cancer, 1994, 73, 118-124.	2.0	171
94	P53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer, 1994, 73, 2147-2156.	2.0	98
95	Diagnostic criteria and cancer risk of proliferative breast lesions. Journal of Cellular Biochemistry, 1993, 53, 59-64.	1.2	19
96	p53: The promising story continues to unfold. Human Pathology, 1993, 24, 455-456.	1.1	21
97	Sclerosing Adenosis and the Risk of Invasive Breast Carcinoma. Surgical Oncology Clinics of North America, 1993, 2, 25-34.	0.6	1
98	Characterization of baculovirus-expressed human .alpha. and .beta. platelet-derived growth factor receptors. Biochemistry, 1992, 31, 10887-10892.	1.2	26
99	Invasive breast cancer risk in women with sclerosing adenosis. Cancer, 1989, 64, 1977-1983.	2.0	169
100	Characterization of Human Brain S100 Protein Fraction: Amino Acid Sequence of S100?. Journal of Neurochemistry, 1985, 45, 700-705.	2.1	92
101	High-Mobility Group (HMG) Protein HMG-1 and TATA-Binding Protein-Associated Factor TAFII30 Affect Estrogen Receptor-Mediated Transcriptional Activation. , 0, .		27